

Curriculum vitae

PERSONAL DATA

Name	Van Herpen
First names	Caroline Marie Louise (Carla)
Date of birth	25 July 1964
Place of birth	Breda
Nationality	Dutch
Personal information	3 children (born 1994, 1996, 2002)
Work Address	Radboud University Medical Center Department of Medical Oncology P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
Phone	+31 24 366 7251
Fax	+31 24 354 0788
E-mail	carla.vanherpen@radboudumc.nl
BIG registration number	99021481001

EDUCATION

- University
1982 - 1989 Medical Study at Catholic University Nijmegen
Graduation as medical doctor, April 1989
- Harvard Business School, Boston, US
2015 - 2016 Managing health care delivery, executive course

CERTIFICATION

- Master of Science in Medicine, July 1986
- Graduation as Medical Doctor, April 1989
- Registration as Specialist in Internal Medicine, June 1995
- Registration as Medical Oncologist, March 1997
- PhD thesis, entitled: "Intratumoral administration of interleukin-12 in head and neck cancer." (2004). Promotor: Prof. Dr. P.H.M. De Mulder, MD, Ph.D., Department of Medical Oncology, Radboud University Medical Center, 2004
- BROK exam, 2009; BROK-update exam 2014

BRIEF CHRONOLOGY OF EMPLOYMENT AND POSITIONS

- 1989 - 1992 Resident internal medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands, (head: Dr. I.H. Go, MD, Ph.D.)
- 1992 - 1995 Resident internal medicine, Radboud University Medical Center, Nijmegen, The Netherlands, (head: Prof. Dr. J.W.M.van der Meer, MD, PhD.)
- 1995 - 1997 Training in medical oncology at the department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands, (head: Prof. Dr. D.J.Th. Wagener, MD, PhD.)
- 1997 – 2002 Research fellow at the department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands, (head: Prof. Dr. P.H.M. De Mulder, MD, PhD.)
- 1997 – 2019 Staff Member at the department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands, (head: Prof. Dr. Prof. dr. ir. J.J.M. van der Hoeven, MD, PhD.)
- 2005 – 2009 "Chef de Clinique", Medical Oncology Clinic, Radboud University Medical Center, Nijmegen, The Netherlands
- 2002 - to date Coordinator of clinical research unit medical oncology, Radboud University Medical Center, Nijmegen, The Netherlands
- 2013 – 2018 Associate Professor in 'Experimental oncology, especially head and neck cancer'
- 2015 - to date Theme leader of 'Rare Cancers', one of the 18 research themes in the Radboud University Medical Center, Nijmegen, The Netherlands
- 2015 – 2019 Coordinator of the Nijmegen Molecular Tumour Board, a multidisciplinary board to treat cancer patients based on tumour mutations, i.e. personalized cancer treatment
- 2018 – to date Professor Rare Cancers at the department Medical Oncology, Radboud University Center, Nijmegen, The Netherlands
- 2019 – to date Head of the department Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands

CLINICAL RESPONSIBILITIES AND RESEARCH INTEREST

Since 1997 I am medical oncologist at the Radboud University Medical Center, Nijmegen. I am active in out-patient care and perform supervision of the clinical ward. Local coordinator of phase 1, 2, 3 studies. Coordinator of the Phase I Unit. Initiator of several translational studies. Member of the head and neck multidisciplinary tumor working team in the hospital. Consultant medical oncologist in several hospitals of the East and South-Netherlands. Since 2018 I was appointed as Professor Rare Cancers. We are a tertiary referral center for salivary gland cancer. I hope to improve the prognosis, to perform (personalized) clinical studies and translational research - from bench to bedside – in patients with salivary gland cancer. Given the rarity of salivary gland cancer I collaborate with international centers and networks.

Since 2019 I am head of the Medical Oncology department of medical oncology in the Radboud University Medical Center.

TEACHING

Several local, locoregional, national and international teaching tasks are performed on a regular base. Coordinator at the department of medical oncology for teaching of students in oncology. Education for medical students, physicians in training, medical oncologists and nurse practitioners in training. Docent mentor in bachelor and master phase of medical students.
jPL predicate since 2016

MEMBERSHIP COMMITTEES AND WORKING PARTIES

Past:

2003	EORTC New Drug Development Group
2007	National guideline committee for hypopharyngeal cancer
2008 and 2010	National guideline committee for laryngeal cancer
2008-2013	Radboud Translational Oncology Programm for targeted therapy
2008-2015	Board member of the NVVO (Nederlandse Vereniging voor Oncologie)
2009-2012	Board member of the EORTC board
2012-2017	Board member Dutch Head and Neck Society
2013-2014	National guideline committee for head and neck cancer

Present:

1997	EORTC Head & Neck Group
2001	Dutch Head and Neck Society
2006	Dutch Immunotherapy Group-Oncology (WIN-O)
2013	Board member Dutch Society of Medical Oncology (NVMO)
2013	Board member of the Dutch Immunotherapy Group-Oncology (WIN-O)
2014	Board member of SONCOS
2014	Member Committee Clinical Scientific Research (ZonMw)
2015	Member of the General Assembly of the EORTC
2015	RIHS research committee (Research institute for Health Sciences)
2016	Co-chairman of committee ('locale uitvoerbaarheid') in the Dutch Clinical Trial Foundation (DCTR) (delegated on behalf of the NFU)

MEMBERSHIP SOCIETIES

Dutch Society of Oncology (NVVO)
Dutch Society of Medical Oncology (NVMO)
Dutch Society of Internists (NIV)
Dutch Head and Neck Society (NWHHT)
Dutch Immunotherapy Group-Oncology (WIN-O)
European Society of Medical Oncology (ESMO)
American Association for Cancer Research (AACR)
American Society of Clinical Oncology (ASCO)

HONOURS AND AWARDS

Awarded as junior Principal Investigator, 2013 to 2015 and 2016 to 2018
Awarded as junior Principal Lecturer, 2016 to 2018
Chair of the jury for societal impact RIHS prize in 2017-10-24
Member of the CZ Expert Advisory Board, since 2017

SUMMARY OF SCIENTIFIC PRODUCTION

H-index: 32

Researcher ID: N-3576-2014

Member of the RIHS (Radboud Institute for Health Sciences)

+/- 185 published articles in peer reviewed journals

+/- 90 communications and lectures

+/- 100 published abstracts

6 published book chapters

PhD THESES

Co-Promotor:

1. Ingrid Desar 22-12-2010: Advanced monitoring of targeted therapy in cancer.
2. Sasja Mulder 28-01-2016: Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors in cancer: treatment related aspects with a focus on quality of life
3. Marye Boers-Sonderen 7-3-2016: Improving outcome and quality of life of cancer patients treated with targeted therapies
4. Annemarie Thijs 17-10-2016: Cardiovascular and metabolic effects of angiogenesis inhibitors

Current PhD students

1. Eline Boon (2018)
2. Chantal Driessen (2018)
3. Janneke Ham (2018)
4. Annelieke Willemsen (2018)
5. Simone Langenberg (2018)
6. Floor Lubberman (2019)
7. Wim van Boxtel (2019)
8. Sarah Verhoeff (2019)

PRESENTATIONS:

1. 2^e WIN-O Symposium: Multidisciplinair symposium on Renal Cell Cancer. Long term treatment with systemic therapie. (Langdurig behandelen met systemische therapie). Dutch. 24 March 2011
2. UMC St Radboud Symposium: Chemoradiation and tumor volume. Indication chemoradiation (Indicatie chemoradiatie) Dutch. 21 April 2011
3. Renal Cell Cancer symposium. Renal Cell Cancer: the new guidelines: current and what is the future? (Niercelcarcinoom: de nieuwe richtlijn: nu en wat is de toekomst?) (Dutch). 29 June 2011
4. Mini-symposium Personalized Medicine: Pharmacogenetics in metastatic renal cell carcinoma (Farmacogenetica bij gemetastaseerd niercelcarcinoom) Dutch. 18 June 2012
5. IFHNOS tour, October 4-6, 2012 Amsterdam, member Scientific Committee
6. NWHHT Congres 2013: report on the CONDOR Study NWHHT 2008-01. (Dutch) 14 March 2013
7. NWHHT Congres 2013: Kosten-effectiviteitsstudie antibiotica profylaxe voor aspiratiepneumonie bij chemoradiatie (PANTAP studie) NWHHT 2011-01. (Dutch) 14 March 2013

8. 1ste Symposium Maatwerk van de Moleculaire Pathologie; Moleculaire Pathologie voor Therapierespons - wat moet u weten... Targeted therapy: the proof of concept. 14 May 2013
9. Oncologie TV: Bijwerkingenmanagement bij de behandeling van mRCC met targeted therapie; alles eruit halen wat er in zit? (Dutch) 29 October 2013, via www.oncologietv.nl
10. Oncologiedagen voor Nederland en Vlaanderen 2013; New and ongoing research, an update (Nieuw en lopend onderzoek, een update) (Dutch). 21 November 2013
11. 4^e WIN-O symposium: Multidisciplinair symposium Renal Cell Cancer. Debate on need for TKI (Dutch). (Debat over TKI-behoefte). 27 March 2014
12. Refereeravond Urologie. Hoe targeted is targeted therapie bij niertumoren? (Dutch). 21 June 2014
13. ESMO: Abstract Discussion MEK162 late breaking abstract, September 29, 2014
14. Berg en Dal Conferentie. Samen verder na kanker-transmurale oncologische nazorg (Dutch). 14 October 2014
15. Invited speaker on Consensus Conference on salivary gland tumors Adenoid-cystic carcinoma and high-grade neoplasm, University of Brescia, October 23-24, 2014
16. Science dag 2014. Synergy in cancer research. 12 November 2014.
17. Oncologiedagen. Ontwikkelingen bij de small molecules en de rol die zij (gaan) spelen bij gepersonaliseerde zorg bij kanker (Dutch). 19 November 2014
18. 5^e WIN-O symposium: Multidisciplinair symposium Renal Cell Cancer. Voortgang lopende studies (Dutch). 11 March 2015
19. Oncologie TV. Therapietrouw in Tijden van Targeted Therapie (Dutch). 8 April 2015.
20. Oncologie TV. Chicago. 2 June 2015
21. Themabijeenkomst HHWG Nijmegen-Arnhem. NWHHT research thema's (Dutch). 1 July 2015.
22. 73st NVvO Oncologiedag/Hemato-Oncologie; member programme commission (Dutch). 30 September 2015
23. jNVMO Head and Neck (Dutch). 18 November 2015.
24. Scholingsdag Nederlandse Vereniging van Oncologie Datamanagers NVvOD. Valkuilen voor (ir-) RECIST (Dutch). Hoe vallen we er niet in? 23 November 2015
25. Radboudumc Science day; Interactions in Oncology. Tumor and optimal targeting. (Dutch). 18 January 2016
26. DNA en kanker voor clinici: van technologie tot toepassing (Dutch). 20 January 2016
27. WIN-O symposium: Multidisciplinair symposium Renal Cell Cancer. Debate on new studies for renal cell cancer patients in the Netherlands (Dutch). 31 March 2016

28. Invited speaker on Congress of the European Society of Pathology/International Academy of Pathology. "Emerging treatments in Head & Neck Squamous Carcinoma". Keulen, September 26, 2016
29. Invited speaker on European Society of Medical Oncology (ESMO) Preceptorship on Immuno-Oncology. Immuno-oncology in head and neck cancer. Amsterdam, October 1, 2016 and May 27, 2017
30. Regionale netwerken: 'denk mee over moleculaire tumorboards in Oost-Nederland. 21-7-2017. Organisator.
31. WIN-O symposium: Multidisciplinair symposium renal cell cancer. Debate on further centralization of the treatment of renal cell cancer is necessary for holding on to quality van care of renal cell cancer patients in the Netherlands (Dutch). 28 March 2019
32. Nieuwspoor, the Hague in the Netherlands. Debat about making the Netherlands one of the five best clinical research countries in the Netherlands. 19 June 2019
33. IAOO 2019, Rome: salivary duct cancer : new developments

PERSONALLY OBTAINED FUNDING (since 2012)

Title project (abbreviated)	Co-applicant research leader(s)	Year granted	Funding body	K € (total grant)
1. Care for the caregivers of cancer patients	W. Van der Graaf, J. Prins	2012	Radboud Institute Oncology	€66.5
2. Head and neck cancer and HPV		2012	Paul Speth fonds	€10
3. Towards patient tailored cancer treatment supported by molecular imaging". IMPACT: IMaging PATients for Cancer drug selection (RUG 2012-5400)	L. de Vries (UMCG), H. Verheul (VUMC); (since 2015 PI)	2012	Alpe d'huZes	€5200
4. Diarrhea during treatment with VEGFR tyrosine kinase inhibitors (TKIs)	M Boers-Sonderen, W van der Graaf	2013	Radboud Oncology Fund together with KWF	€5.5
5. EORTC 1206: study to hormonal treatment in salivary gland cancer AR+	J. Buter, S. Oosting	2014	KWF	€19.3
6. The search towards new treatment for patients with salivary gland cancer		2016	Radboud Oncology Fund together with KWF	€202
7. PET/CT imaging of PD-L1 expression in cancer patients	S. Heskamp	2016	Radboud Insitute	€240

to predict response to immune checkpoint inhibitors			Health Sciences	
8. PET/CT imaging of Durvalumab expression in head and neck cancer to predict response to immune checkpoint inhibitors	S. Heskamp	2017	Astra Zeneca	€400
9. PET/CT imaging of avelumab expression in lung cancer patients to predict response to immune checkpoint inhibitors	S. Heskamp	2017	Merck	€450
10. PSMA-PET imaging for advanced ACC/SDC		2017	ACC Research Foundation	€25
11. Lu-PSMA therapy for salivary gland cancer		2018	Dutch cancer Foundation	€658
12. The (immunological) microenvironment of salivary gland cancers		2018-2019	ROF/Dutch Cancer Foundation	€300

PUBLICATIONS

1. Katan MB, Kruyswyk Z, van Herpen CML, Demacker PMJ, Stalenhoef AFH. Fingerprick cholesterol testing the "reflotron". Clin Chem 1988;34:1007 (Letter)
2. Vreugdenhil G, van Herpen CML, Koene RAP. Erythropoietin versus iron chelators in anaemia and iron overload. Neth J Med 1993;42:45-47 (Editorial)
3. Van Herpen CML, van Hoesel QGCM, Punt CJA. Paclitaxel-induced severe hypersensitivity reaction occurring as a late toxicity. Ann Oncol 1995;6:852 (Letter)
4. Punt CJA, van Herpen CML, Jansen RHL, Vreugdenhil A, Muller EW, de Mulder PHM. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon- γ for metastatic melanoma: a multicentre phase II study. Br J Cancer 1997;76:266-269
5. Van Herpen CML, de Mulder PHM. Immunologie in de medische praktijk. XVII. Immunotherapie bij het gemetastaseerde niercelcarcinoom. Ned Tijds Geneesk 1998;48:2613-2618
6. Van Herpen CML, Jansen RHL, de Goey SH, Hoekman K, Groenewegen G, de Mulder PHM on behalf of the Dutch Immunotherapy Working Party. Immunochemotherapy with Interleukin-2, Interferon- γ and 5-Fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study Br J Cancer 2000;82:772-776
7. Van Herpen CML and de Mulder PHM. Locoregional immunotherapy in cancer patients: Review of clinical studies. Ann Oncol 2000;11:1229-1239
8. Van Herpen CML, de Mulder PHM. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma. Critical reviews in Oncology /Hematology 2002;41:327-334
9. van Herpen CML, Huijbens R, Looman M, de Vries J, Marres H, van de Ven J, Hermsen R, Adema G and de Mulder PH. Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human Interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in PBMCs. Clin Cancer Res 2003;9:2950-2956
10. Schrijvers D, Van Herpen C, Kerger J, Joosens E, Van Laer C, Awada A, Van Den Weyngaert D, Nguyen H, Le Boudier C, Castelijns JA, Kaanders J, de Mulder P, Vermorken JB. Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol. 2004; 15:638-645
11. Van Damme PA, van Herpen CM, Meis JF. An adult case of oral infection with Kingella kingae. Int J Oral Maxillofac Surg. 2004;33:105-107.
12. Van Herpen CML, Looman M, Zonneveld M, Scharenborg N, de Wilde P, van de Locht L, Merx MAW, Adema GJ and de Mulder PHM. Intratumoral administration of rhIL-12 in head and neck squamous cell carcinoma patients elicits a T helper 1 profile in the locoregional lymph nodes. Clinical Cancer Research 2004;10:2626-2635
13. De Mulder PH, van Herpen C, Mulder PA. Current treatment of renal cell carcinoma. Ann Oncol. 2004;15 Suppl 4:iv319-28. Review
14. van Herpen CML, Bussink J, van der Kogel AJ, Peeters WJM, van der Voort R, van Schijndel A, de Wilde PCM, Adema GJ and De Mulder PHM. Interleukin-12 has no effect on vascular density, perfusion, hypoxia, and proliferation of an implanted human squamous cell carcinoma xenograft

tumour despite upregulation of ICAM-1. *Anticancer Res.* 2005 Mar-Apr;25(2A):1015-1021.

15. van Herpen CML, van der Laak JAWM, de Vries IJM, van Krieken JH, de Wilde PC, Balvers MGJ, Adema GJ, de Mulder PHM. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients modifies the locoregional lymph node architecture and induces a NK cell infiltration in the primary tumor. *Clin Cancer Res.* 2005 Mar 1;11(5):1899-1909.

16. Hendrickx B, van Herpen C, Bonenkamp J, Bulten J, Oyen W. Positive positron emission tomography scan in sarcoidosis and two challenging cases of metastatic cancer. CASE 1. Mediastinal sarcoidosis in a melanoma patient treated with interferon. *J Clin Oncol.* 2005 Dec 1;23(34):8906-8907.

17. Bosch T, Huitema A, Doodeman V, Jansen R, Witteveen E, Smit M, Jansen R, van Herpen C, Soesan M, Beijnen J, Schellens J. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. *Clin Cancer Res.* 2006 Oct 1;12(19):5786-5793.

18. Dekker H, van Herpen C, Hoogeveen Y, Thomsen H, Ruers T, Barentsz J. CMR 2005: 14.04: Oral manganese as contrast medium in detecting liver metastases with MR imaging at 1.5 and 3 T. *Contrast Media Mol Imaging.* 2006 Mar;1(2):90-91

19. Soetekouw PM, Gijtenbeek JM, van der Maazen RW, Kappelle AC, van Herpen CM. [Temozolomide, an oral chemotherapeutic agent with potential severe toxicity]. *Ned Tijdschr Geneeskd.* 2007 Jan 27;151(4):253-257.

20. Serfass L, van Herpen C, Saghatchian M. Molecular targets and cancer therapeutics. *Eur J Cancer.* 2007;43:1493-1495

21. Vermorcken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart S, Jelic S, Betka J, Preiss J, van den Weyngaert D, Awada A, Cupissol D, Kienzer H, Rey A, Desauois I, Bernier J, Lefebvre J-L, for the EORTC 24971/TAX 323 Study Group. Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer. *New England Journal of Medicine* 2007; 357:11-20

22. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet.* 2008 Aug 9;372(9637):449-456

23. van Herpen CM, van der Voort R, van der Laak JA, Klasen IS, de Graaf AO, van Kempen LC, de Vries IJ, Boer TD, Dolstra H, Torensma R, van Krieken JH, Adema GJ, de Mulder PH. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B-cell activation. *Int J Cancer.* 2008 Nov 15;123(10):2354-2361

24. van Herpen CM, Locati LD, Buter J, Thomas J, Bogaerts J, Lacombe D, de Mulder P, Awada A, Licitra L, Bernier J, Vermorcken JB. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). *Eur J Cancer.* 2008 Nov;44(17): 2542-2545

25. Berends M, van Bokhoven MM, van de Luitgaarden A, Bellersen LB, van Hoesel QC, van Herpen CM. [Ventricular assist device implantation as a bridge to cardiac transplantation in two adolescents with end-stage cardiomyopathy and heart failure as a result of anthracycline use]. *Ned Tijdschr Geneeskd.* 2008 Sep 20;152(38):2088-2092

26. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT.

Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. *Cancer Treat Rev.* 2009 Jun;35(4):309-321

27. Desar IM, Burger DM, Van Hoesel QG, Beijnen JH, Van Herpen CM, van der Graaf WT. Pharmacokinetics of sunitinib in an obese patient with a GIST. *Ann Oncol.* 2009 Mar;20(3):599-600
28. Nutting CM, van Herpen CM, Miah AB, Bhide SA, Machiels JP, Buter J, Kelly C, de Raucourt D, Harrington KJ. Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. *Ann Oncol.* 2009 Jul;20(7):1275-1279
29. Stewart JS, Cohen EE, Licitra L, van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. *J Clin Oncol.* 2009 Apr 10;27(11):1864-1871. Erratum in: *J Clin Oncol.* 2009 Jul 10;27(20):3410.
30. Mannaerts L, Bleeker-Rovers CP, Koopman M, Punt CJ, van Herpen CM. Pylephlebitis after a duodenal ulcer in a patient with metastasised colon carcinoma treated with chemotherapy and bevacizumab: a case report. *Neth J Med.* 2009 Feb;67(2):69-71
31. Desar IM, Mulder SF, Stillebroer AB, van Spronsen DJ, van der Graaf WT, Mulders PF, van Herpen CM. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. *Acta Oncol.* 2009;48(6):927-931
32. van Herpen CM, van der Graaf WT, Oyen WJ. Time to target evaluation criteria of targeted therapies. *Nucl Med Commun.* 2009 Jul;30(7):487-489
33. Gregorc V, Santoro A, Bennicelli E, Punt CJ, Citterio G, Timmer-Bonte JN, Caligaris Cappio F, Lambiase A, Bordignon C, van Herpen CM. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. *Br J Cancer.* 2009 Jul 21;101(2):219-224
34. Janssens GO, van Herpen CM. [Diagnostic image; a man with severe radiation dermatitis]. *Ned Tijdschr Geneeskd.* 2009;153:B413
35. Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, Blum HE, Fiedler W, Dreys J, Le Maulf F, Fielding A, Robertson J, Voest EE. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. *J Clin Oncol.* 2009 Dec 20;27(36):6152-6159
36. van Herpen CML, de Boer JP, Rasch CRN, Kaanders JHAM. De Condor Studie: een gerandomiseerde fase-II studie met chemotherapie met Docetaxel/cisplatine/5-fluorouracil gevolgd door concomitante chemo-radiotherapie met conventionele radiotherapie of met geaccelereerde radiotherapie bij patiënten met lokaal uitgebreide hoofd-halskanker, die in goede conditie zijn. Een studie van de Nederlandse Werkgroep Hoofd-Hals-Tumoren (NWHHT 08-01). *Ned. Tijdschr. Oncol.* 2009;6:40-42
37. Desar IM, Bovenschen HJ, Timmer-Bonte AJ, Cantarini MV, van der Graaf WT, van Rossum MM, van Herpen CM. Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours. *Acta Oncol.* 2010;49(1):110-113

38. van Cruijssen H, Voest EE, Punt CJ, Hoekman K, Witteveen PO, Meijerink MR, Puchalski TA, Robertson J, Saunders O, Jürgensmeier JM, van Herpen CM, Giaccone G. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. *Eur J Cancer*. 2010 Mar;46(5):901-911
39. Quak E, van Laarhoven HW, Bos H, Bouwhuis JW, van Herpen CM, van der Graaf WT. [Diarrhoea and fever in chemotherapy patients due to listeriosis]. *Ned Tijdschr Geneeskd*. 2010;154(24):A1645. Dutch.
40. Desar IM, Sonderen MJ, van Herpen CM. A patient with renal cell carcinoma and thoracic pain. *Neth J Med*. 2010 May;68(5):229-232
41. Bussink J, van Herpen CM, Kaanders JH, Oyen WJ. PET-CT for response assessment and treatment adaptation in head and neck cancer. *Lancet Oncol*. 2010 Jul;11(7):661-669
42. Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM. The first-in-human study of the hydrogen sulphate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. *Clin Cancer Res*. 2010 Mar 1;16(5):1613-1623
43. Desar IM, Gilles R, van Herpen CM, Timmer-Bonte AJ, Cantarini MV, van der Graaf WT, Oyen WJ. (18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors. *World J Nucl Med*. 2012 May;11(2):65-69
44. van Laarhoven HW, Fiedler W, Desar IM, van Asten JJ, Marréaud S, Lacombe D, Govaerts AS, Bogaerts J, Lasch P, Timmer-Bonte JN, Lambiase A, Bordignon C, Punt CJ, Heerschap A, van Herpen CM. Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). *Clin Cancer Res*. 2010 Feb 15;16(4):1315-1323
45. Desar IM, Timmer-Bonte JN, Burger DM, van der Graaf WT, van Herpen CM. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer. *Br J Cancer*. 2010 Nov 23;103(11):1637-1643
46. Prinsen H, de Vries IJ, Torensma R, Pots JM, Mulder SF, van Herpen CM, Elving LD, Bleijenberg G, Stelma FF, van Laarhoven HW. Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome. *BMC Immunol*. 2012 Dec 17;13:71
47. Desar IM, Stillebroer AB, Oosterwijk E, Leenders WP, van Herpen CM, van der Graaf WT, Boerman OC, Mulders PF, Oyen WJ. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. *J Nucl Med*. 2010 Nov;51(11):1707-1715.
48. van Herpen CM, Eskens FA, de Jonge M, Desar I, Hooftman L, Bone EA, Timmer-Bonte JN, Verweij J. A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours. *Br J Cancer*. 2010 Oct 26;103(9):1362-1368
49. van Herpen CM, Mauer ME, Mesia R, Degardin M, Jelic S, Coens C, Betka J, Bernier J, Remenar E, Stewart JS, Preiss JH, van den Weyngaert D, Bottomley A, Vermorken JB; EORTC Head and Neck Group. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable

locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). *Br J Cancer*. 2010 Oct 12;103(8):1173-1181

50. Thijs AM, van der Graaf WT, van Herpen CM. Temsirolimus for metastatic desmoplastic small round cell tumor. *Pediatr Blood Cancer*. 2010 Dec 15;55(7):1431-1432

51. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. *Cancer*. 2010 Sep 15;116(18):4256-4265

52. Desar IM, van Herpen CM, van Asten JJ, Fiedler W, Marreaud S, Timmer-Bonte JN, Ter Voert EG, Lambiase A, Bordignon C, Heerschap A, van Laarhoven HW. Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients. *Eur J Radiol*. 2011;80(3):655-661

53. Rütten H, Pop LA, Janssens GO, Takes RP, Knuijt S, Rooijackers AF, van den Berg M, Merckx MA, van Herpen CM, Kaanders JH. Long-Term Outcome and Morbidity After Treatment with Accelerated Radiotherapy and Weekly Cisplatin for Locally Advanced Head-and-Neck Cancer: Results of a Multidisciplinary Late Morbidity Clinic. *Int J Radiat Oncol Biol Phys*. 2011 Nov 15;81(4):923-929

54. Willemsen AE, van Herpen CM, Wesseling P, Bult P, van Laarhoven HW. Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma. *Acta Oncol*. 2011 Apr;50(3):462-465

55. Desar IM, Jacobs JF, Hulsbergen-Van de Kaa CA, Oyen WJ, Mulders PF, van der Graaf WT, Adema GJ, van Herpen CM, de Vries IJ. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. *Int J Cancer*. 2011 Jul 15;129(2):507-512

56. Pappaspyrou G, Hoch S, Rinaldo A, Rodrigo JP, Takes RP, van Herpen C, Werner JA, Ferlito A. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: A review. *Head Neck*. 2011 Jun;33(6):905-911

57. Kneijens JL, Hauptmann M, Pameijer FA, Balm AJ, Hoebbers FJ, de Bois JA, Kaanders JH, van Herpen CM, Verhoef CG, Wijers OB, Wiggeraad RG, Buter J, Rasch CR. Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. *Head Neck*. 2011 Mar;33(3):375-382

58. Schellekens AF, Mulder SF, van Eijndhoven PF, Smilde TJ, van Herpen CM. Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases. *Gen Hosp Psychiatry*. 2011 Jan-Feb;33(1):83.e1-3

59. Grünwald V, Desar IM, Haanen J, Fiedler W, Mouritzen U, Olsen MW, van Herpen CM. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). *Acta Oncol*. 2011 Jan;50(1):121-126

60. Jaspers HC, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, van der Graaf WT, van Herpen CM. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. *J Clin Oncol*. 2011 Jun 1;29(16):e473-476

61. Füssenich LM, Desar IM, Peters ME, Teerenstra S, van der Graaf WT, Timmer-Bonte JN, van Herpen CM. A new, simple and objective prognostic score for phase I cancer patients. *Eur J Cancer*. 2011 May;47(8):1152-1160

62. Aben KK, Heskamp S, Janssen-Heijnen ML, Koldewijn EL, van Herpen CM, Kiemeneij LA, Oosterwijk E, van Spronsen DJ. Better survival in patients with metastasised kidney cancer after nephrectomy: A population-based study in the Netherlands. *Eur J Cancer*. 2011 Sep;47(13):2023-2032
63. Kats-Ugurlu G, Maass C, van Herpen C, de Waal R, Oosterwijk E, Mulders P, Hulsbergen-van de Kaa C, Leenders W. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production. *Histopathology*. 2011 Sep;59(3):562-564
64. Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, Schreiber G, de Boer A, Van Herpen CM, Kaanders JH, van Krieken JH, Adema GJ, Figdor CG, de Vries IJ. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. *J Clin Invest*. 2011 Aug 1;121(8):3100-3108
65. Mulder SF, Jacobs JF, Olde Nordkamp MA, Galama JM, Desar IM, Torensma R, Teerenstra S, Mulders PF, Vissers KC, Punt CJ, de Vries IJ, van Herpen CM. Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. *Clin Cancer Res*. 2011 Jul 1;17(13):4541-4549
66. Desar IM, Ter Voert EG, Hambroek T, van Asten JJ, van Spronsen DJ, Mulders PF, Heerschap A, van der Graaf WT, van Laarhoven HW, van Herpen CM. Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. *Cancer Imaging*. 2012 Jan 12;11(1):259-265
67. Desar IM, Thijs AM, Mulder SF, Tack CJ, van Herpen CM, van der Graaf WT. Weight loss induced by tyrosine kinase inhibitors of the vascular endothelial growth factor pathway. *Anticancer Drugs*. 2012 Feb;23(2):149-154
68. Verwimp-Hoeks MP, van Herpen CM, Burger DM. Aprepitant quetiapine: a clinically significant drug interaction in a patient treated for head and neck cancer. *Ann Oncol*. 2012 Mar;23(3):801-802
69. Van Herpen CML, Teerenstra S, Desar IME, van der Graaf WTA. Reply letter to: Pitfalls and limitations of a single-centre retrospectively derived prognostic score for phase I oncology trial participant – Reply to Füssenich et al: a new, simple and objective prognostic score for phase I cancer patients. *Eur J Cancer* 2012; 48:597-598
70. Boers-Sonderen MJ, Desar IM, Blokx W, Timmer-Bonte JN, van Herpen CM. A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244). *Anti-Cancer Drugs* 2012;23(7):761-764.
71. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiles JP, Lee, SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. *Eur J Cancer* 2012;48(3):324-332.
72. Urba S, van Herpen CM, Sahoo TP, Shin DM, Licitra L, Mezei K, Reuter C, Hitt R, Russo F, Chang SC, Hossain AM, Fridmott-Moller B, Koustenis A, Hong RL. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: Final results of a randomized, double-blind, placebo-controlled, phase 3 study. *Cancer*. 2012 Oct

1;118(19):4694-705.

73. van de Schans SA, Aben KK, Mulders PF, Haanen JB, van Herpen C, Verhoeven RH, Karim-Kos HE, Oosterwijk E, Kiemeny LA. Modest improvement in 20years of kidney cancer care in the Netherlands. *Eur J Cancer*. 2012 Aug;48(12):1822-30.
74. De Vos FY, Driessen CM, Jaspers HC, van Herpen CM, Simons B. Cetuximab-induced pneumonitis in head and neck cancer patient. *Oral Oncol*. 2012;48(6):e17-18.
75. Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E, Protheroe A, van Herpen CM, Mookerjee B, Pike L, Jürgensmeier JM, Gore ME. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. *Eur J Cancer*. 2012 Mar;48(4):527-537.
76. Boers-Sonderen MJ, Desar IM, Blokk W, Timmer-Bonte JN, van Herpen CM. A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244). *Anticancer Drugs*. [Research Support, Non-U.S. Gov't]. 2012 Aug;23(7):761-4.
77. Den Deurwaarder ES, Desar IM, Steenbergen EJ, Mulders PF, Wetzels JFM, van Herpen CM. Kidney injury during VEGF inhibitor therapy. *Neth J Med*. 2012 Aug;70(6):267-71.
78. Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, Guchelaar HJ, Reyners AK, van Herpen CM, Haanen JB, Mathijssen RH, Boven E. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. *Clin Pharmacol Ther*. 2012 Oct;92(4):503-10.
79. Franceschi E, Stupp R, van den Bent MJ, van Herpen C, Laigle Donadey F, Gorlia T, Hegi M, Lhermitte B, Strauss LC, Allgeier A, Lacombe D, Brandes AA. EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. *Neuro Oncol*. 2012 Oct 25.
80. Boers-Sonderen M, Desar I, Van Der Graaf WTA, Ottevanger PB, Van Herpen C. A phase Ib study of the combination of temsirolimus (T) and pegylated liposomal doxorubicin (PLD) in advanced or recurrent breast, endometrial, and ovarian cancer. *J Clin Oncol* 2012; 3(18) (suppl; abstr 5061)
81. van Herpen CM, Lassen U, Desar IM, Brown KH, Marotti M, de Jonge MJ. Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment. *Anti-Cancer Drugs* 2013, 24(2): 204-11
82. Hoeben BA, Troost EG, Span PN, van Herpen CM, Bussink J, Oyen WJ, Kaanders JH. 18F-FLT PET During Radiotherapy or Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Is an Early Predictor of Outcome. *J Nucl Med*. 2013 Apr;54(4):532-40
83. Driessen CM, van Rossum MM, Blokk WA, van Herpen CM. Skin lesions in a patient with head and neck cancer. *Neth J Med*. 2013; 71(9):481-485
84. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. *Lancet Oncol*. 2013;14(3):249-256
85. Boers-Sonderen MJ, Desar IM, Koopman M, Punt CJ, van Herpen CM. Capecitabine,

irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer. *Acta Oncol.* 2013;52(8):1778

86. De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, van Herpen CM. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. *Crit Rev Oncol Hematol.* 2013;85(3):373-382
87. Hamberg P, Boers-Sonderen MJ, van der Graaf WT, de Bruijn P, Suttle AB, Eskens FA, Verweij J, van Herpen CM, Sleijfer S. Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study. *Br J Cancer.* 2014 Feb 18;110(4) 888-99.
88. Schoffelen R, Boerman OC, Goldenberg DM, Sharkey RM, van Herpen CM, Franssen GM, McBride WJ, Chang CH, Rossi EA, van der Graaf WT, Oyen WJ. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. *Br J Cancer.* 2013 Aug 20;109(4):934-942
89. Thijs AM, van Herpen CM, Sweep FC, Geurts-Moespot A, Smits P, van der Graaf WT, Rongen GA. Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans. *Hypertension.* 2013 May;61(5):1060-1065
90. Willemsen AE, van Herpen CM. mTOR inhibitor-related pulmonary toxicity; incidence even higher. *Acta Oncol.* 2013 Aug;52(6):1234.
91. Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ; RECORD-1 Trial Study Group. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. *Eur Urol.* 2013 Dec;64(6):994-1002.
92. Stillebroer AB, Boerman OC, Desar IM, Boers-Sonderen MJ, van Herpen CM, Langenhuijsen JF, Smith-Jones PM, Oosterwijk E, Oyen WJ, Mulders PF. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. *Eur Urol.* 2013 Sep;64(3):478-85.
93. Hendriks MP, Driessen CM, van Laarhoven HW, Janssens GO, Verbist BM, van der Graaf WT, Slootweg PJ, Merks MA, van Herpen CM. Aggressive fibromatosis in the head and neck region: Benign tumor with often mutilating effects. *Head Neck.* 2013 Aug;35(8):E246-50.
94. Mulder SF, Boers-Sonderen MJ, van der Heijden HF, Vissers KC, Punt CJ, van Herpen CM. A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion. *Target Oncol.* 2014 Jan 21.
95. Versleijen MW, Verbist BM, Mulder JJ, de Geus-Oei LF, van Herpen CM. Avastin Scintigraphy in Surveillance of Bevacizumab Treatment in a Patient With Neurofibromatosis Type 2: A Case Report. *Clin Nucl Med.* 2014 Mar;39(3):277-80.
96. Willemsen AE, Grutters JC, Gerritsen WR, Tol J, van Herpen CM. Caution for interstitial lung disease as a cause of CA 15-3 rise in advanced breast cancer patients treated with everolimus. *Int J Cancer.* 2014 Aug 15;135(4):1007.
97. Muselaers CH, Stillebroer AB, Desar IM, Boers-Sonderen MJ, van Herpen CM, de Weijert MC, Langenhuijsen JF, Oosterwijk E, Leenders WP, Boerman OC, Mulders PF, Oyen WJ. Tyrosine Kinase Inhibitor Sorafenib Decreases 111In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma. *J Nucl Med.* 2014 Feb;55(2):242-7.

98. Boers-Sonderen MJ, Mulder SF, Nagtegaal ID, Jacobs JF, Wanten GJ, Hoentjen F, van Herpen CM. Severe exacerbation of Crohn's disease during sunitinib treatment. *Eur J Gastroenterol Hepatol.* 2014 Feb;26(2):234-6.
99. van den Berg MG, Rütten H, Rasmussen-Conrad EL, Knuijt S, Takes RP, van Herpen CM, Wanten GJ, Kaanders JH, Merkx MA. Nutritional status, food intake, and dysphagia in long-term survivors with head and neck cancer treated with chemoradiotherapy: A cross-sectional study. *Head Neck.* 2014 Jan;36(1):60-65
100. Boers-Sonderen MJ, van Herpen CM, van der Graaf WT, Desar IM, van der Logt MG, de Beer YM, Ottevanger PB, van Erp NP. Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®). *Cancer Chemother Pharmacol.* 2014 Sep;74(3):457-63
101. Grebenchtchikov N, Geurts-Moespot AJ, Heijmen L, van Laarhoven HW, van Herpen CM, Thijs AM, Span PN, Sweep FC. Quantification of patient specific assay interference in different formats of enzyme linked immunoassays for therapeutic monoclonal antibodies. *Ther Drug Monit.* 2014 Dec;36(6): 765-70
102. Kats-Ugurlu G, Oosterwijk E, Muselaers S, Oosterwijk-Wakka J, Hulsbergen-van de Kaa C, de Weijert M, van Krieken H, Desar I, van Herpen C, Maass C, de Waal R, Mulders P, Leenders W. Neoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments. *Neoplasia.* 2014 Mar;16(3):221-8
103. Fleuren ED, Versleijen-Jonkers YM, Heskamp S, van Herpen CM, Oyen WJ, van der Graaf WT, Boerman OC. Theranostic applications of antibodies in oncology. *Mol Oncol.* 2014 Jun;8(4):799-812
104. Küsters-Vandeveldde HV, Willemsen AE, Groenen PJ, Küsters B, Lammens M, Wesseling P, Djafarihamedani M, Rijntjes J, Delye H, Willemsen MA, van Herpen CM, Blokx WA. Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor. *Acta Neuropathol Commun.* 2014 Apr 8;2(1):41
105. Mulder SF, Bertens D, Desar IM, Vissers KC, Mulders PF, Punt CJ, van Spronsen DJ, Langenhuijsen JF, Kessels RP, van Herpen CM. Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study. *BMC Cancer.* 2014 Mar 24;14:219.
106. Willemsen AE, De Vos FY, Jansen A, de Boer M, Tjan-Heijnen VC, van Herpen CM. Diagnostic challenges of respiratory adverse events during everolimus treatment. *Target Oncol.* 2014 Sep; 9(3):287-91
107. Boers-Sonderen MJ, de Geus-Oei LF, Desar IM, van der Graaf WT, Oyen WJ, Ottevanger PB, van Herpen CM. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. *Target Oncol.* 2014 Dec; 9(4):339-47
108. Hoeben BA, Troost EG, Bussink J, van Herpen CM, Oyen WJ, Kaanders JH. 18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients. *Nuklearmedizin.* 2014;53(2):60-6
109. Vlenterie M, Desar IM, van Herpen CM, Tol J. Fatal microscopic pulmonary tumour embolisms in patients with breast cancer: necessary knowledge for future medical practice. *Neth J Med.* 2014 Jan;72(1):28-31.

110. Willemsen AE, Grutters JC, van Erp NP, Gerritsen WR, Tol J en van Herpen, C.; De PREVENT studie: een prospectieve analyse van everolimus-geïnduceerde interstitiële longziekte. *Nederlands tijdschrift voor Oncologie* 2014 Sep;11(6):244-248
111. Prinsen H, van Laarhoven HW, Pots JM, Duiveman-de Boer T, Mulder SF, van Herpen CM, Jacobs JF, Leer JW, Bleijenberg G, Stelma FF, Torensma R, de Vries IJ. Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue. *Hum Vaccin Immunother.* 2015;11(7):1634-40.
112. Birzele F, Voss E, Nopora A, Honold K, Heil F, Lohmann S, Verheul H, Le Tourneau C, Delord JP, van Herpen C, Mahalingam D, Coveler AL, Meresse V, Weigand S, Runza V, Cannarile M. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. *Clin Cancer Res.* 2015 Jun 15;21(12):2753-62.
113. Thijs AM, El Messaoudi S, Vos JC, Wouterse AC, Verweij V, van Swieten H, van Herpen CM, van der Graaf WT, Noyez L, Rongen GA.. Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle. *Target Oncol.* 2015 Sep;10(3):439-43.
114. van Dijk EH, van Herpen CM, Marinkovic M, Haanen JB, Amundson D, Luyten GP, Jager MJ, Kapiteijn EH, Keunen JE, Adamus G, Boon CJ. Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. *Ophthalmology.* 2015 Sep;122(9):1907-16.
115. Thijs AM, van Herpen CM, Verweij V, Pertijs J, van den Broek PH, van der Graaf WT, Rongen GA. Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension. *J Hypertens.* 2015 Oct;33(10):2075-82.
116. Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR.. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. *Cancer Chemother Pharmacol.* 2015 Oct;76(4):723-9.
117. Boers-Sonderen MJ, Desar IM, Fütterer JJ, Mulder SF, De Geus-Oei LF, Mulders PF, Van Der Graaf WT, Oyen WJ, Van Herpen CM.. Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. *Anticancer Res.* 2015 Oct;35(10):5601-6.
118. Hollander Dd, Kampman E, van Herpen CM.. Pretreatment body mass index and head and neck cancer outcome: A review of the literature. *Crit Rev Oncol Hematol.* 2015 Nov;96(2):328-38.
119. Derikx LA, Nissen LH, Drenth JP, van Herpen CM, Kievit W, Verhoeven RH, Mulders PF, Hulsbergen-van de Kaa CA, Boers-Sonderen MJ, van den Heuvel TR, Pierik M, Nagtegaal ID, Hoentjen F.. Better survival of renal cell carcinoma in patients with inflammatory bowel disease. *Oncotarget.* 2015 Nov 10;6(35):38336-38347.
120. Muselaers CH, Boers-Sonderen MJ, van Oostenbrugge TJ, Boerman OC, Desar IM, Stillebroer AB, Mulder SF, van Herpen CM, Langenhuijsen JF, Oosterwijk E, Oyen WJ, Mulders PF. Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. *Eur Urol.* 2016 May; 69(5):767-70.
121. Langenberg SM, Peters ME, van der Graaf WT, Wymenga AN, Prins JB, van Herpen CM.. How did partners experience cancer patients' participation in a phase I study? An observational study after a patient's death. *Palliat Support Care.* 2016 Jun;14(3):341-9

122. Driessen CM, de Boer JP, Gelderblom H, Rasch CR, de Jong MA, Verbist BM, Melchers WJ, Tesselaaar ME, van der Graaf WT, Kaanders JH, van Herpen CM. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study. *Eur J Cancer*. 2016 Jan;52:77-84.
123. Ham JC, Verhoef CG, van Herpen CM. Acute erythema of the face after methotrexate. *Neth J Med*. 2016 Jan;74(1):49-50
124. Van der Linden N, Buter J, Pescott CP, Lalisang RI, de Boer JP, de Graeff A, van Herpen CM, Baatenburg de Jong RJ, Uyl-de Groot CA. Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands. *Eur Arch Otorhinolaryngol*. 2016 Feb;273(2):455-64
125. Willemsen AE, Vlenterie M, van Herpen CM, van Erp NP, van der Graaf WT, de Geus-Oei LF, Oyen WJ. Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [18F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid tumours: All that glitters is not gold. *Eur J Cancer*. 2016 Mar;56:54-8
126. Van den Berg MG, Kalf JG, Hendriks JC, Takes RP, van Herpen CM, Wanten GJ, Drenth JP, Kaanders JH, Merkx MA. Normalcy of food intake in patients with head and neck cancer supported by combined dietary counseling and swallowing therapy: A randomized clinical trial. *Head Neck*. 2016 Apr; 38 Suppl 1:E198-206.
127. Driessen CM, Janssens GO, van der Graaf WT, Takes RP, Merkx TA, Melchers WJ, Kaanders HA, van Herpen CM. Toxicity and efficacy of accelerated radiotherapy with concurrent weekly cisplatin for locally advanced head and neck carcinoma. *Head Neck*. 2016 Apr;38 Suppl 1:E559-65.
128. Thijs AM, Tack CJ, van der Graaf WT, Rongen GA, van Herpen CM. The early effect of sunitinib on insulin clearance in patients with metastatic renal cell carcinoma. *Br J Clin Pharmacol*. 2016 Apr;81(4):768-72
129. Visser NC, van der Heijden EH, van Herpen CM, Looijen M, Slootweg PJ. Low-grade salivary duct carcinoma in the bronchus. *Histopathology*. 2016 Apr;68(5):758-60
130. Driessen CM, Uijen MJ, van der Graaf WT, van Opstal CC, Kaanders JH, Nijenhuis T, van Herpen CM. Degree of nephrotoxicity after intermediate- or high-dose cisplatin-based chemoradiotherapy in patients with locally advanced head and neck cancer. *Head Neck*. 2016 Apr;38 Suppl 1:E1575-81
131. Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. *Int J Cancer*. 2016 May 15;138(10):2312-21.
132. Cerbone L, Sternberg CN, Sengeløv L, Agerbaek M, Van Herpen C, Marreaud S, Collette S, Zhang J, Daugaard G. Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061. *Oncology*. 2016;90(1):21-8
133. Willemsen AE, Lubberman FJ, Tol J, Gerritsen WR, van Herpen CM, van Erp NP. Effect of

food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. *Drug Discov Today*. 2016 Jun;21(6):962-76.

134. Desar IM, van Herpen CM, van Erp NP, Kaal SE, van de Kerkhof PC, van der Graaf WT. A successful approach to overcome imatinib-induced skin toxicity in a GIST patient. *Anticancer Drugs*. 2016 Jul;27(6):576-9.

135. Boers-Sonderen MJ, Mulder SF, Nagtegaal ID, Derikx LA, Wanten GJ, Mulders PF, van der Graaf WT, Hoentjen F, van Herpen CM. Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa? *Acta Oncol*. 2016;55(4):444-8

136. Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C, Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sørensen M, Soetekouw P, van Herpen C, Fielding A, So K, Bannister W, Plummer R. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. *Clin Ther*. 2016 Oct;38(10):2286-2299.

137. Hoeben A, van de Winkel L, Hoebbers F, Kross K, Driessen C, Slootweg P, Tjan-Heijnen VC, van Herpen C. Intestinal-type sinonasal adenocarcinomas: The road to molecular diagnosis and personalized treatment. *Head Neck*. 2016 Oct;38(10):1564-70

138. Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HM, van der Graaf WT, Christen R, Rüttinger D, Weigand S, Cannarile MA, Heil F, Brewster M, Walz AC, Nayak TK, Guarin E, Meresse V, Le Tourneau C. First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. *Oncotarget*. 2016 Nov 29;7(48):80046-80058.

139v van Herpen CH, Koekkoek WA, Ramrattan RS, Tjan DH. [Shock-induced ischemic optic neuropathy]. *Ned Tijdschr Geneesk*. 2016;160(0):A9831. Dutch.

140. Takes RP, Kaanders JH, van Herpen CM, Merckx MA, Slootweg PJ, Melchers WJ. A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. *J Clin Virol*. 2016 Dec;85:22-26

141. Takes RP, Kaanders JH, van Herpen CM, Merckx MA, Slootweg PJ, Melchers WJ. Human papillomavirus detection in fine needle aspiration cytology of lymph node metastasis of head and neck squamous cell cancer. *J Clin Virol*. 2016 Dec;85:22-26

2017

142. Boon E, van der Graaf WT, Gelderblom H, Tesselaar ME, van Es RJ, Oosting SF, de Bree R, van Meerten E, Hoeben A, Smeele LE, Willems SM, Witjes MJ, Buter J, Baatenburg de Jong RJ, Flucke UE, Peer PG, Bovée JV, Van Herpen CM. Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. *Head Neck*. 2017 Jan;39(1):140-146.

143. Lubberman FJ, van Erp NP, Ter Heine R, van Herpen CM. Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal. *Acta Oncol*. 2017 Apr 7:1-3.

144. Ham JC, Tops BBJ, Driessen CML, van Raaij AWM, Slootweg PJ, Melchers WJG, Ligtenberg MJL, van Herpen CML. Using a semi-conductor sequencing-based panel for genotyping of HPV-positive and HPV-negative oropharyngeal cancer: a retrospective pilot study. *Clin Otolaryngol*. 2017 Jun;42(3):681-686.

145. Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.
Psyrris A, Fortpied C, Koutsodontis G, Avgeris M, Kroupis C, Goutas N, Menis J, Herman L, Giurgea L, Remenár É, Degardin M, Pateras IS, Langendijk JA, van Herpen CML, Awada A, Germà-Lluch JR, Kienzer HR, Licitra L, Vermorken JB. *Ann Oncol.* 2017 Sep 1;28(9):2213-2218. doi: 10.1093/annonc/mdx320.
146. Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma.
van Boxtel W, Boon E, Weijs WLJ, van den Hoogen FJA, Flucke UE, van Herpen CML. *Oral Oncol.* 2017 Sep;72:198-200.
147. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwiński R, Poulsen M, O'Sullivan B, Corvò R, Laskar SG, Fallai C, Yamazaki H, Dobrowsky W, Cho KH, Garden AS, Langendijk JA, Viegas CMP, Hay J, Lotayef M, Parmar MKB, Aupérin A, van Herpen C, Maingon P, Trotti AM, Grau C, Pignon JP, Blanchard P; MARCH Collaborative Group. *Lancet Oncol.* 2017 Sep;18(9):1221-1237
148. Lankheet NAG, Desai IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, van der Graaf WTA, van Erp NP. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. *Br J Clin Pharmacol.* 2017 Oct;83(10):2195-2204
149. Caetano-Pinto P, Jamalpoor A, Ham J, Goumenou A, Mommersteeg M, Pijnenburg D, Ruijtenbeek R, Sanchez-Romero N, van Zelst B, Heil SG, Jansen J, Wilmer MJ, van Herpen CML, Masereeuw R. Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters. *Mol Pharm* 2017 May 24 [Epub ahead of print]
150. Hato SV, Figdor CG, Takahashi S, Pen AE, Halilovic A, Bol KF, Vasaturo A, Inoue Y, de Haas N, Verweij D, Van Herpen CML, Kaanders JH, van Krieken JHJM, Van Laarhoven HWM, Hooijer GKJ, Punt CJA, Asai A, de Vries IJM, Lesterhuis WJ. Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. *Oncotarget.* 2017 May [Epub ahead of print]
151. Daanen RA, Maas RJH, Koornstra RHT, Steenbergen EJ, van Herpen CML, Willemsen AECAB. Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report. *J Immunother.* 2017 Nov/Dec;40(9):345-348.
152. van der Velden DL, van Herpen CML, van Laarhoven HWM, Smit EF, Groen HJM, Willems SM, Nederlof PM, Langenberg MHG, Cuppen E, Sleijfer S, Steeghs N, Voest EE. Molecular Tumor Boards: Current Practice and Future Needs. *Ann Oncol.* 2017 Sep 27.
153. [Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.](#)
Schöffski P, Wozniak A, Escudier B, Rutkowski P, Anthony A, Bauer S, Sufliarsky J, van Herpen C, Lindner LH, Grünwald V, Zakotnik B, Lerut E, Debiec-Rychter M, Marréaud S, Lia M, Raveloarivahy T, Collette S, Albiges L.
Eur J Cancer. 2017 Dec;87:147-163
154. [Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer.](#)
Willemsen AECAB, Knapen LM, de Beer YM, Brüggemann RJM, Croes S, van Herpen CML, van Erp NP.

Eur J Clin Pharmacol. 2018 Apr;74(4):465-471.

155. [Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial.](#)

Driessen CML, Groenewoud JMM, de Boer JP, Gelderblom H, van der Graaf WTA, Prins JB, Kaanders JHAM, van Herpen CML.
Support Care Cancer. 2018 Apr;26(4):1233-1242.

156. [Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.](#)

Boon E, van Boxtel W, Buter J, Baatenburg de Jong RJ, van Es RJJ, Bel M, Fiets E, Oosting SF, Slingerland M, Hoeben A, Tesselaar MET, Jonker MA, Flucke UE; Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) Group, van der Graaf WTA, van Herpen CML.
Head Neck. 2018 Mar;40(3):605-613.

157. [A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.](#)

van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML.
Invest New Drugs. 2018 Oct;36(5):828-835.

158. [A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.](#)

Boon E, Bel M, van Boxtel W, van der Graaf WTA, van Es RJJ, Eerenstein SEJ, Baatenburg de Jong RJ, van den Brekel MWM, van der Velden LA, Witjes MJH, Hoeben A, Willems SM, Bloemena E, Smit LA, Oosting SF; PALGA Group, Jonker MA, Flucke UE, van Herpen CML.
Int J Cancer. 2018 Aug 15;143(4):758-766.

159. [A pharmacological rationale for improved everolimus dosing in oncology and transplant patients.](#)

Ter Heine R, van Erp NP, Guchelaar HJ, de Fijter JW, Reinders MEJ, van Herpen CM, Burger DM, Moes DJAR.
Br J Clin Pharmacol. 2018 Jul;84(7):1575-1586

160. [Drug-drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy.](#)

Schoffelen R, Lankheet AG, van Herpen CML, van der Hoeven JJM, Desar IME, Kramers C.
Neth J Med. 2018 Apr;76(3):109-114. Review.

161. [Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed \(mammary analogue\) secretory carcinoma of salivary glands.](#)

Boon E, Valstar MH, van der Graaf WTA, Bloemena E, Willems SM, Meeuwis CA, Slootweg PJ, Smit LA, Merx MAW, Takes RP, Kaanders JHAM, Groenen PJTA, Flucke UE, van Herpen CML.
Oral Oncol. 2018 Jul;82:29-33.

162. [Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane.](#)

Willemsen AECAB, de Geus-Oei LF, de Boer M, Tol J, Kamm Y, de Jong PC, Jonker MA, Vos AH, Grootjans W, de Groot JWB, Mulder SF, Aarntzen EHJG, Gerritsen WR, van Herpen CML, van Erp NP.
Target Oncol. 2018 Oct;13(5):641-648.

163. [Caregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor \(TKI\) for gastrointestinal stromal tumour \(GIST\): a cross-sectional assessment of their distress and burden.](#)

Langenberg SMCH, Reyners AKL, Wymenga ANM, Sieling GCM, Veldhoven CMM, van Herpen CML, Prins JB, van der Graaf WTA.
Acta Oncol. 2019 Feb;58(2):191-199.

- 164.** [Toxicity-induced modification of treatment: what is in a name?](#)
Kok DE, Winkels RM, van Herpen CM, Kampman E.
Eur J Cancer. 2018 Nov;104:145-150.
- 165.** [Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients.](#)
Bins S, Huitema ADR, Laven P, Bouazzaoui SE, Yu H, van Erp N, van Herpen C, Hamberg P, Gelderblom H, Steeghs N, Sleijfer S, van Schaik RHN, Mathijssen RHJ, Koolen SLW.
Clin Pharmacokinet. 2019 May;58(5):651-658.
- 166.** [Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.](#)
Huijts CM, Werter IM, Lougheed SM, Goedegebuure RS, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.
Cancer Immunol Immunother. 2019 Feb;68(2):319-329.
- 167.** [Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy.](#)
Driessen CML, Leijendeckers J, Snik A, van der Graaf WTA, de Boer JP, Gelderblom H, Kaanders JHAM, Takes R, van Herpen CML.
Head Neck. 2019 Feb;41(2):488-494.
- 168.** [The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.](#)
Huijts CM, Lougheed SM, Bodalal Z, van Herpen CM, Hamberg P, Tascilar M, Haanen JB, Verheul HM, de Gruijl TD, van der Vliet HJ; Dutch WIN-O Consortium.
Cancer Immunol Immunother. 2019 Mar;68(3):503-515.
- 169.** [53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.](#)
Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.
Gynecol Oncol. 2019 Apr;153(1):127-134
- 170.** [Risk Factors and Clinical Outcomes of Head and Neck Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study.](#)
Nissen LHC, Derikx LAAP, Jacobs AME, van Herpen CM, Kievit W, Verhoeven R, van den Broek E, Bekers E, van den Heuvel T, Pierik M, Rahamat-Langendoen J, Takes RP, Melchers WJG, Nagtegaal ID, Hoentjen F; Dutch Initiative on Crohn and Colitis (ICC); Dutch Head and Neck Society, PALGA group; IBD/HNC group.
Inflamm Bowel Dis. 2018 Aug 16;24(9):2015-2026.
- 171.** [Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.](#)
van Boxtel W, Locati LD, van Engen-van Grunsven ACH, Bergamini C, Jonker MA, Fiets E, Cavaliere S, Tooten S, Bos E, Quattrone P, Verhaegh GW, Schalken JA, Licitra L, van Herpen CML; PALGA Group.
Eur J Cancer. 2019 Mar;110:62-70.
- 172.** [Caregivers' burden and fatigue during and after patients' treatment with concomitant chemoradiotherapy for locally advanced head and neck cancer: a prospective, observational pilot study.](#)
Langenberg SMCH, van Herpen CML, van Opstal CCM, Wymenga ANM, van der Graaf WTA, Prins JB.
Support Care Cancer. 2019 Feb 22.
- 173.** [Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.](#)

Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, van Herpen CML, van Erp NP.
Lancet Oncol. 2019 Apr;20(4):e200-e207

174. [Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib \(MEK162\) in patients with advanced NRAS- or BRAF-mutated melanoma.](#)

van Herpen CML, Agarwala SS, Hauschild A, Berking C, Beck JT, Schadendorf D, Jansen R, Queirolo P, Ascierto PA, Blank CU, Heinrich MC, Pal RR, Derti A, Antona V, Nauwelaerts H, Zubeil A, Dummer R.
Oncotarget. 2019 Mar 5;10(19):1850-1859.

175. [Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study.](#)

Ham JC, Driessen CM, Hendriks MP, Fiets E, Kreike B, Hoeben A, Slingerland M, van Opstal CC, Kullberg BJ, Jonker MA, Adang EM, Kaanders JH, van der Graaf WT, van Herpen CM.
Eur J Cancer. 2019 May;113:32-40.

176. [Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy \(The PRONE Study\).](#)

Driessen CM, Ham JC, Te Loo M, van Meerten E, van Lamoen M, Hakobjan MH, Takes RP, van der Graaf WT, Kaanders JH, Coenen MJH, van Herpen CM.
Cancers (Basel). 2019 Apr 17;11(4).

177. [Whole-body hyperthermia in combination with systemic therapy in advanced solid malignancies.](#)

Lassche G, Crezee J, Van Herpen CML.
Crit Rev Oncol Hematol. 2019 Jul;139:67-74.

178. [The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference \(DIET Study\).](#)

Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP.
Clin Pharmacol Ther. 2019 May 24.

179. [Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.](#)

Willemsen AECAB, Krausz S, Ligtenberg MJL, Grünberg K, Groen HJM, Voest EE, Cuppen EPJG, van Laarhoven HWM, van Herpen CML.
Br J Cancer. 2019 Jul;121(1):34-36

180. [Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution - Authors' reply.](#)

Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, van Herpen CML, van Erp NP.
Lancet Oncol. 2019 Jun;20(6):e290.

181. [Lesion detection by \[⁸⁹Zr\]Zr-DFO-girentuximab and \[¹⁸F\]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.](#)

Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, Oosting SF, Aarntzen EH, Brouwers AH, Kwee TC, Heskamp S, Hoekstra OS, Verheul H, van der Veldt AAM, de Vries EGE, Boerman OC, van der Graaf WTA, Oyen WJG, van Herpen CML.
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1931-1939

182. [Prevalence and clinical and psychological correlates of high fear of cancer recurrence in patients newly diagnosed with head and neck cancer.](#)

Mirosevic S, Thewes B, van Herpen C, Kaanders J, Merckx T, Humphris G, Baatenburg de Jong RJ, Langendijk JA, Leemans CR, Terhaard CHJ, Verdonck-de Leeuw IM, Takes R, Prins J; NET-QUBIC Consortium.

Head Neck. 2019 Sep;41(9):3187-3200.

183. [Improving survival in salivary duct cancer with adjuvant androgen deprivation therapy.](#)

van Bortel W, van Herpen C.

Oncotarget. 2019 Jun 11;10(39):3833-3834.

184. [Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.](#)

Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P.

Lancet Oncol. 2019 Aug;20(8):1124-1135.

185. [Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.](#)

van Es SC, van der Vegt B, Bensch F, Gerritse S, van Helden EJ, Boon E, Angus L, Overbosch J, Menke-van der Houven van Oordt CW, Verheul HM, van Herpen CML, Jager A, Oosting SF, de Vries EGE, Schröder CP.

Am J Surg Pathol. 2019 Oct;43(10):1355-1360.

186. [Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane.](#)

Willemsen AECAB, Tol J, van Erp NP, Jonker MA, de Boer M, Meek B, de Jong PC, van Moorsel C, Gerritsen WR, Grutters JC, van Herpen CML.

Target Oncol. 2019 Aug;14(4):441-451

187. [RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.](#)

van Helden EJ, Angus L, Menke-van der Houven van Oordt CW, Heideman DAM, Boon E, van Es SC, Radema SA, van Herpen CML, de Groot DJA, de Vries EGE, Jansen MPH, Sleijfer S, Verheul HMW.

Mol Oncol. 2019 Jul 26.

188. [Health-related quality of life of patients treated with chemoradiotherapy plus or minus prophylactic antibiotics to reduce the number of pneumonias for locally advanced head and neck cancer, the PANTAP study.](#)

Ham JC, van Herpen CML, Driessen CML, van der Graaf WTA, Husson O.

Oral Oncol. 2019 Sep;96:105-112.

189. [Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors.](#)

van De Ven SEM, Derikx LAAP, Nagtegaal ID, van Herpen CM, Takes RP, Melchers WJG, Pierik M, van den Heuvel T, Verhoeven RHA, Hoentjen F, Nissen LHC.

Inflamm Bowel Dis. 2019 Sep 27.